Sharda CropchemQ1 FY27
Sharda Cropchem Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹765P/E: 11.0Market Cap: ₹6.9K CrSector: Fertilizers & Agrochemicals
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →The company maintains FY27 revenue growth guidance of 10%-15%.
- →Volume growth for the year is expected around 10%, with recovery anticipated particularly in Europe after a slower Q1.
- →Europe is expected to rebound strongly in the next three quarters, recovering from weather-related volume decline.
- →NAFTA and LATAM regions have shown strong volume growth in Q1 and are expected to maintain momentum.
- →Future growth is expected from both volume increases and new product additions with higher realizations.
- →The company anticipates sustained investment in product registrations to support long-term growth.
- →Overall, all three key markets (Europe, NAFTA, LATAM) are expected to contribute positively to growth going forward.
Margin guidance
Category 3- →The company expects sustained revenue growth of 10%-15% for FY27.
- →Gross margins are anticipated to remain in the range of 35% to 37%.
- →EBITDA margin guidance is maintained at 18%-20%.
- →Operating performance shows strength with PBT (excluding FOREX impact) growth of 16% YoY.
- →Europe volumes are expected to recover strongly over the next three quarters, helping overall growth.
- →NAFTA and LATAM regions continue to show strong growth momentum.
- →New product additions along with volume growth are expected to drive future earnings growth.
- →Management remains cautiously optimistic given external factors like weather and currency volatility but is focused on long-term growth through sustained investments.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no indication in the document of any current or planned fundraising through debt or equity.
- →The company remains debt-free as of June 30, 2026.
- →The company has a strong cash, bank, and liquid investment position of Rs. 767 crores as of June 30, 2026, up from Rs. 702 crores as of March 31, 2026.
- →The management has not mentioned any plans to raise capital through debt or equity.
- →Capex guidance remains around Rs. 500 crores for the year, with no upward revision despite higher spending in Q1.
- →The company appears focused on organic growth and sustained investment in product registrations without external fundraising.
Order book
The transcript from Sharda Cropchem Limited's Q1 FY 2026-27 earnings call does not explicitly mention details regarding the current or expected order book or pending orders. However, some relevant points that indirectly touch on order-related aspects are:
- The company faces uncertainties related to registrations and product acceptance impacting future orders.
- The management highlighted strong registration pipelines, noting ongoing efforts to sustain and grow product registrations, which is integral to securing future sales.
- The volume growth outlook for FY27 is expected at 5% to 10%, indicating anticipated order flow improvement.
- Improvement in European volumes is expected after a weak first quarter impacted by weather.
- LATAM and NAFTA regions showed strong growth, indicating healthy order intake there.
- The company maintains a positive outlook on revenue growth of 10%-15% for FY27.
No specific figures or details on order book size or pending orders were disclosed.
Capex plans
Yes- →Sharda Cropchem continues to invest significantly in intangible CAPEX, mainly product registrations, with annual investment around Rs. 450-500 crores.
- →The high CAPEX of Rs. 273 crores in Q1 FY27 included some unusual data compensation spend but the company has not revised its full-year CAPEX guidance.
- →Full-year CAPEX guidance remains around Rs. 500 crores despite higher Q1 spend.
- →The company emphasizes that registration activities are full of uncertainties with timelines and costs unpredictable.
- →Investments in new product registrations are ongoing and crucial for long-term growth and margin improvement.
- →The amortization related to these new registrations impacts quarterly results but is expected to stabilize on an annualized basis.
- →No specific mention of strategic acquisitions or expansions beyond registration investments.
How does Sharda Cropchem rank vs peers in Fertilizers & Agrochemicals?
Pro feature1Sharda Cropchem
Rev 3Mar 3
See full Fertilizers & Agrochemicals sector rankings
How does Sharda Cropchem rank in Fertilizers & Agrochemicals?
Compare Sharda Cropchem against every Fertilizers & Agrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.